IL1B and COVID-19: Our results showed that serum IL-1β levels were not elevated in severe COVID-19 patients compared to nonsevere patients (P = 0.33) (Figure 2(a)), while levels of IL-1β were elevated in nonsurvivor COVID-19 patients compared to survivors (WMD = 0.20, 95% CI: 0.15-0.24, and P < 0.01) (Figure 2(b)).